title: Repeat brachytherapy for patients with residual or recurrent tumors of oral cavity.
abstract: OBJECTIVE
  To analyze data from patients receiving repeat brachytherapy (re-BT) for the treatment of residual or recurrent tumor in the oral cavity.
  
  
  METHODS
  Between January 2003 and December 2007, 62 patients who had undergone definitive BT as an initial treatment of oral cancer subsequently underwent re-BT for the treatment of residual or recurrent tumors at the diagnostic radiology and oncology department (Tokyo Medical and Dental University Hospital). Re-BT was performed 0.9-73 months (median, 5.7) after the initial BT. Au-198 grains were used as the re-BT source in all 62 patients, and an area of 0.8-6.3 cm(2) (median, 3.1) was permanently irradiated with 60-110 Gy (median, 83) according to the system of Paterson-Parker.
  
  
  RESULTS
  The 2-year local control and overall survival rate was 53% and 66%, respectively, and local control significantly affected overall survival. Both local control and overall survival were affected by the initial tumor characteristics and the macroscopic appearance of the residual or recurrent tumor. Grade 3 or 4 complications were seen in 5 patients. The incidence of mandibular and mucosal complications was significantly related to a biologic effective dose of α/β of 3 Gy to the surface of the gingiva and mucosa, respectively.
  
  
  CONCLUSIONS
  Re-BT using Au-198 grains for the treatment of residual or recurrent tumor after definitive BT in the oral cavity is effective and well tolerated.
authors.affiliation: Department of Diagnostic Radiology and Oncology, Tokyo Medical and Dental University, Tokyo, Japan. ysmrmrad@tmd.ac.jp
authors.forename: Ryo-Ichi
authors.initials: R
authors.lastname: Yoshimura
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Shibuya
authors.forename: Keiji
authors.initials: K
authors.lastname: Hayashi
authors.forename: Keiko
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Kazuma
authors.initials: K
authors.lastname: Toda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Watanabe
authors.forename: Atushi
authors.initials: A
authors.lastname: Kaida
authors.forename: Masahiko
authors.initials: M
authors.lastname: Miura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D006050:Gold Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000532:radiotherapy*; D018365:Neoplasm, Residual; D011879:Radiotherapy Dosage; D019233:Retreatment / Q000379:methods / Q000401:mortality; D012189:Retrospective Studies
chemical_list: D006050:Gold Radioisotopes